Retraction Note: Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19

Affiliations

¹ Department of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.
² African Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
³ Faculty of Clinical Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
⁴ Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁵ Afe Babalola University, Ekiti state, Nigeria.
⁶ University of West England, Coldharbour Ln, Stoke Gifford, Bristol, UK.
⁷ Department of community Health, Lagos State University College of Medicine, Ikeja Lagos, Nigeria.
⁸ Department of Medicine, Faculty of Clinical Sciences, Bayero University, Kano state, Nigeria.
⁹ Department of Medicine, V.N Karazin Kharkiv National University, Svobody Square, Kharkiv, Ukraine. chuku2016.6391200@student.karazin.ua.

Adewunmi Akingbola et al. NPJ Vaccines. 2025.

. 2025 Dec 24;10(1):265.

doi: 10.1038/s41541-025-01353-0.

¹ Department of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.
² African Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
³ Faculty of Clinical Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
⁴ Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁵ Afe Babalola University, Ekiti state, Nigeria.
⁶ University of West England, Coldharbour Ln, Stoke Gifford, Bristol, UK.
⁷ Department of community Health, Lagos State University College of Medicine, Ikeja Lagos, Nigeria.
⁸ Department of Medicine, Faculty of Clinical Sciences, Bayero University, Kano state, Nigeria.
⁹ Department of Medicine, V.N Karazin Kharkiv National University, Svobody Square, Kharkiv, Ukraine. chuku2016.6391200@student.karazin.ua.

No abstract available

Retraction of

Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.
Akingbola A, Adegbesan A, Adegoke K, Idahor C, Mariaria P, Peters F, Salami RA, Ojo O, Nwaeze E, Abdullahi O, Chuku J. Akingbola A, et al. NPJ Vaccines. 2025 May 24;10(1):105. doi: 10.1038/s41541-025-01145-6. NPJ Vaccines. 2025. Retraction in: NPJ Vaccines. 2025 Dec 24;10(1):265. doi: 10.1038/s41541-025-01353-0. PMID: 40413212 Free PMC article. Retracted. Review.

1. Wang, Y. et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines. Front. Cell. Infect. Microbiol.14, 1412478 (2024). - DOI - PMC - PubMed
1. Stepanova, E. et al. Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza. Virol. J.21, 82 (2024). - DOI - PMC - PubMed
1. Ye, Q. et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines7, 84 (2022). - DOI - PMC - PubMed
1. Domnich, A. et al. COVID-19 and seasonal influenza vaccination: cross-protection, co-administration, combination vaccines, and hesitancy. Pharmaceuticals15, 322 (2022). - DOI - PMC - PubMed
1. Focosi, D. From co-administration to co-formulation: the race for new vaccines against COVID-19 and other respiratory viruses. Vaccines11, 109 (2023). - DOI - PMC - PubMed